Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

NET 5Endocrine 5

Conditions

Neuroendocrine Tumors 5Multiple Endocrine Neoplasia Type 1 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × lenvatinib × NET × Clear all
NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
45 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
36 enrolled
EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 12 charts
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02678780 2025-07-24

TALENT

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
123 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡